First Percutaneous Lifelong RV Support

Right ventricular (RV) dysfunction is a life-threatening condition, leaving patients with right-sided heart failure with few—if any—truly effective treatment options. Current minimally invasive solutions provide only temporary support, often resulting in long, incomplete recoveries, while long-term support requires major, high-risk surgery.

Today, nearly 3 million people in Europe and the United States live with right heart dysfunction. For approximately 300,000 to 150,000 of them—those with end-stage heart failure (5-10%)—RV support is a necessity. RV dysfunction typically arises from increased RV afterload, and the majority (65%) also suffer from severe tricuspid regurgitation. Yet, current treatments fall short: 50% of these patients are ineligible for tricuspid therapy due to anatomical constraints, 20% do not respond because of advanced disease, and 35% do not have severe tricuspid regurgitation.

The need for innovation has never been more urgent.